Poised to become the first company to achieve a regulatory filing for a cell therapy in autoimmune disease, Kyverna Therapeutics is building a pipeline-in-a-product to change the treatment paradigm
Tesofensine produced weight loss significantly greater than placebo and was more effective than any currently approved obesity drug at the time. Astrup et al., The Lancet Additional Findings: The majority of weight loss came from visceral fat and abdominal adiposity Lean body mass was preserved , unlike with most appetite suppressants Participants reported reduced hunger and better diet adherence Tesofensine significantly improved waist circumference , lipid profiles, and fasting glucose These findings have led to continued interest in Tesofensines use for body recomposition not just for general weight loss, but for fat-specific reduction without muscle sacrifice
Patients whose primary goal is maximum weight loss and who want the drug with the strongest efficacy data Those who have plateaued on semaglutide and need a more potent treatment Adults with obesity and obstructive sleep apnea (the only FDA-approved pharmacotherapy for OSA) Type 2 diabetes patients who need stronger HbA1c reduction beyond what semaglutide can provide Patients for whom insurance covers tirzepatide at comparable or lower cost to semaglutide Who should choose semaglutide
Limit screen time: Avoid phones and TVs at least an hour before bed
While semaglutide is known for its effectiveness in controlling blood sugar and helping with weight loss, some people may wonder if it causes painful urination
